Difference between revisions of "Bevacizumab-adcd (Vegzelga)"
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "[https://online.lexi.com/lco/action/login UpToDate Lexidrug]") |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
Line 5: | Line 5: | ||
<br>Extravasation: [[neutral]] | <br>Extravasation: [[neutral]] | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/drug/avastin-bevacizumab-342257 Medscape],[http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== |
Latest revision as of 01:47, 29 June 2024
Note: this is an FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication and the references.
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Carcinoma of unknown primary
- Anaplastic glioma
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Colorectal cancer
- Esophageal cancer
- Follicular lymphoma
- Glioblastoma
- Hepatocellular carcinoma
- Melanoma
- Malignant pleural mesothelioma
- Neuroendocrine tumor
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic NET
- Renal cell carcinoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
- Endometrial cancer
- Vascular sarcoma
History of changes in FDA indication
- 2022-09-28: Approved for metastatic colorectal cancer, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Based on CT-P16 3.1)
Also known as
- Code name: CT-P16
- Brand name: Vegzelga, Vegzelma
References
- CT-P16 3.1: Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, Yañez Ruiz E, Kim S, Ahn K, Park T, Park S, Ju H, Ohe Y. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. BioDrugs. 2022 Nov;36(6):749-760. Epub 2022 Sep 28. link to original article PubMed NCT03676192
- Drugs
- Intravenous medications
- Neutral
- Anti-VEGF antibodies
- Carcinoma of unknown primary medications
- Anaplastic glioma medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colorectal cancer medications
- Esophageal cancer medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hepatocellular carcinoma medications
- Melanoma medications
- Malignant pleural mesothelioma medications
- Neuroendocrine tumor medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Endometrial cancer medications
- Vascular sarcoma medications
- FDA approved in 2022
- Biosimilars